CATALOGO DEI PRODOTTI DELLA RICERCA

QUAGLIA, Francesca Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.110
NA - Nord America 2.564
AS - Asia 2.234
SA - Sud America 260
AF - Africa 193
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.382
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.413
RU - Federazione Russa 1.667
SG - Singapore 875
IT - Italia 704
VN - Vietnam 311
CN - Cina 301
BD - Bangladesh 280
BR - Brasile 175
HK - Hong Kong 171
GB - Regno Unito 170
DE - Germania 106
BJ - Benin 87
IN - India 83
FR - Francia 81
CA - Canada 66
SE - Svezia 55
NL - Olanda 54
MX - Messico 51
ES - Italia 47
IE - Irlanda 44
NG - Nigeria 37
PL - Polonia 37
FI - Finlandia 34
JP - Giappone 34
AR - Argentina 29
ID - Indonesia 29
AT - Austria 22
KR - Corea 22
TR - Turchia 22
ZA - Sudafrica 20
TN - Tunisia 18
AU - Australia 17
EC - Ecuador 16
IQ - Iraq 12
RO - Romania 12
PT - Portogallo 11
SA - Arabia Saudita 11
PH - Filippine 10
PK - Pakistan 10
UA - Ucraina 10
VE - Venezuela 10
CH - Svizzera 9
CO - Colombia 9
EG - Egitto 9
HN - Honduras 9
BE - Belgio 8
IL - Israele 8
CL - Cile 7
LT - Lituania 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
GR - Grecia 6
PS - Palestinian Territory 6
TH - Thailandia 6
IR - Iran 5
JM - Giamaica 5
MY - Malesia 5
PY - Paraguay 5
QA - Qatar 5
ET - Etiopia 4
NI - Nicaragua 4
PE - Perù 4
TG - Togo 4
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
LB - Libano 3
MA - Marocco 3
TW - Taiwan 3
UZ - Uzbekistan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CG - Congo 2
DZ - Algeria 2
GE - Georgia 2
HR - Croazia 2
KE - Kenya 2
KZ - Kazakistan 2
MD - Moldavia 2
MT - Malta 2
NP - Nepal 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
GY - Guiana 1
HU - Ungheria 1
JO - Giordania 1
KW - Kuwait 1
Totale 8.372
Salva come PNG Salva come JPEG
Città #
Moscow 716
San Jose 555
Singapore 520
Ashburn 409
Verona 229
Dallas 172
Hong Kong 165
New York 129
Council Bluffs 111
Ho Chi Minh City 97
Chandler 96
Los Angeles 89
Cotonou 87
Hanoi 71
Beijing 69
Milan 55
Buffalo 53
Orem 48
Dublin 42
London 37
The Dalles 36
Bologna 35
Rome 32
São Paulo 32
Warsaw 32
Mexico City 28
Santa Clara 28
Chennai 26
Montreal 26
Tokyo 26
Xi'an 23
Denver 22
Munich 21
Toronto 21
Atlanta 20
Brooklyn 20
Stockholm 20
Abuja 19
Houston 19
Haiphong 18
Helsinki 18
Lagos 18
Da Nang 17
Naples 17
Poplar 17
Jacksonville 15
Johannesburg 15
Frankfurt am Main 14
Jakarta 14
Querétaro 14
Southend 14
Manchester 13
Mumbai 13
Phoenix 13
Seattle 13
Amsterdam 12
Falkenstein 11
Melbourne 11
Padua 11
Boston 10
Bucharest 10
Lawrence 10
Lisbon 10
Madrid 10
Princeton 10
Stuttgart 10
Wilmington 10
Boardman 9
Tianjin 9
Venice 9
Vienna 9
Ankara 8
Belfast 8
City of London 8
Dong Ket 8
Jinan 8
Lappeenranta 8
Redondo Beach 8
Turin 8
Bari 7
Chicago 7
Columbus 7
Hyderabad 7
Hürth 7
New Delhi 7
Ninh Bình 7
Tunis 7
Brussels 6
Catania 6
Charlotte 6
Guangzhou 6
Guayaquil 6
Istanbul 6
Nuremberg 6
Paris 6
Philadelphia 6
Seoul 6
Bắc Ninh 5
Dhaka 5
Doha 5
Totale 4.835
Salva come PNG Salva come JPEG
Nome #
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 232
Fentanyl buccal tablet: a new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease. 203
Chronic lymphocytic leukemia and mantle cell lymphoma: similarities and differences from an integrated biological and clinical approach 201
The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia 192
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 181
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 177
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 177
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 176
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 169
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 165
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 160
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 160
Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease 157
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 146
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 141
Bendamustine plus rituximab: is it a BRIGHT idea? 140
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 138
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 120
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 116
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 113
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 107
Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature 100
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 97
THE ROLE OF STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 91
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 90
IN CHRONIC LYMPHOCYTIC LEUKAEMIA WITH COMPLEX KARYOTYPE, MAJOR STRUCTURAL ABNORMALITIES IDENTI- FY A SUBSET OF PATIENTS WITH INFERIOR OUTCOME AND DISTINCT BIOLOGIC CHARACTERISTICS 90
SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE 87
R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy 86
BCR signaling activity stratifies patents with MCL with divergent clinical outcome 85
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF THE B-CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA 84
A phospho-specific flow cytometry study reveals the impact of BCR signaling activation in mantle cell lymphoma progression and therapy 81
B-CELL RECEPTOR SIGNALING ACTIVITY IDENTIFIES PATIENTS WITH MANTLE CELL LYMPHOMA AT HIGHER RISK OF PROGRESSION 81
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation 80
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 80
ARGO, AUTOMATIC RECORD GENERATOR IN ONCOLOGY: MULTICENTRIC VALIDATION OF A NEW TOOL FOR AUTO- MATIC CONVERSION OF “REAL-LIFE” HEMOLYMPHOPATHOL- OGY REPORTS IN STANDARDIZED ECRF 78
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920) 78
ACTIVATION OF BCR SIGNALING REWIRES THE RESPONSE OF BCR-ASSOCIATED KINASES TO IBRUTINIB IN MANTLE CELL LYMPHOMA CELLS 77
THE PROGNOSTIC ROLE OF DEL 9P21.3 (CDKN2A) IN PATIENTS WITH MANTLE CELL LYMPHOMA. RESULTS FROM THE FIL_MANTLE-FIRST BIO STUDY 76
GENETIC AND EPIGENETIC MECHANISMS REGULATING CATALASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA 75
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study 74
DIFFERENT MICROENVIRONMENTAL PATTERNS OF T-CELL INFILTRATION CAN IDENTIFY MANTLE CELL LYMPHOMA PATIENTS WITH DISTINCT CLINICAL OUTCOMES. RESULTS FROM A PILOT CLINICAL-PATHOLOGICAL STUDY 73
FITNESS STATUS AND TIME TO FIRST PROGRESSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE “ELDERLY MANTLE-FIRST” STUDY 73
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study 68
B-CELL RECEPTOR SIGNALING PROFILES IN MANTLE CELL LYMPHOMA: A BARCODING AND PHOSPHO-SPECIFIC FLOW CYTOMETRY APPROACH 67
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations 67
Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs 66
OUTCOME OF 100 TP53-DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED FRONT-LINE WITH IBRUTINIB. A REAL-LIFE CAMPUS CLL STUDY. 65
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 64
B-CELL RECEPTOR SIGNALING PROFILES IDENTIFY SUBSETS OF MANTLE CELL LYMPHOMA PATIENTS WITH DIFFERENT CLINICAL OUTCOMES 63
A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEX- AMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRAC- TORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP 63
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 62
A MULTI‐CENTER REAL‐LIFE ANALYSIS ON PATIENTS WITH LARGE B‐CELL LYMPHOMA AFTER FAILURE OF CAR‐T CELLS THERAPY 61
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. 60
THE PROGNOSTIC SIGNIFICANCE OF MYC AND BCL2 PROTEIN DOUBLE EXPRESSION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, NOS, IN THE ABSENCE OF MYC REARRANGEMENT 60
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 59
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 59
Association of genetic polymorphisms with differential catalase gene expression in prognostic groups of chronic lymphocytic leukemia patients. 58
RESPONSE TO IBRUTINIB OF AN AGGRESSIVE IG-A LYMPHOPLASMACYTIC LYMPHOMA CARRYING THE MYD88 L265P GENE MUTATION 57
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 57
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL) 55
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report 55
OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYM- PHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY 54
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL‐LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 54
Worldwide Examination of Patients with CLL Hospitalized for COVID-19 54
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 53
Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus 53
Callosal agenesis in craniofrontonasal dysplasia 52
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.” 52
CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS 52
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study 51
Paraaortic PEComa 51
Atherosclerotic ectasia of coronary arteries 50
HBV REACTIVATION IN CLL PATIENTS WITH OCCULT HBV INFECTION TREATED WITH IBRUTINIB WITH OR WITHOUT VIRAL PROPHYLAXIS. A RETROSPECTIVE MULTICENTRIC GIMEMA STUDY 49
Recurrent infiltrative cancer of the cheek: a case report 48
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 48
AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS 48
Simultaneous abdominal histoplasmosis and cerebral toxoplasmosis in an AIDS patient 47
VALIDATION OF AN INFECTION RISK SYSTEM IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE IDELALISIB-RITUXIMAB REGIMEN 46
Left main coronary artery aneurysm 45
Notch signaling is a poor prognostic factor in Acute Myeloid Leukemia (AML). 45
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 45
Brachial aneurysm following arterovenous fistula ligation 45
Fluorescent cell barcoding and phospho-specific flow cytometry characterize B-cell receptor signaling profiles associated with different clinical outcome in mantle cell lymphoma 45
Diagnosis of groove pancreatitis in patient with chronic pancreatitis and recurrent abdominal pain 44
Regulation of catalase gene expression in chronic lymphocytic leukemia patients. 44
Cavernous sinus thrombosis: exophtalmos in a patient with Internal Carotid Artery (ICA) aneurysm 44
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 44
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 43
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: results from the ELDERLY MANTLE-FIRST study 43
Gastroepiploic artery bypass graft 43
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 42
Subacute combined degeneration 42
The presentation of a possible effect induced by human contact with a source of high voltage electrical current 41
Ultrasound guided radiofrequency thermoablation of thyroid substernal goiter 40
Preoperative visualisation of Adamkiewicz artery by computed tomography in a patient with aortic aneurysm 40
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 39
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 39
Extensive NGS analysis in untreated CLL patients: clinical and biological correlations 38
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion 37
Squamous cell carcinoma of the penis: a case report 37
Totale 8.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.300
article - articoli 12.935
book - libri 0
conference - conferenze 6.210
curatela - curatele 0
other - altro 2.155
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.600
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/202279 2 19 0 5 11 5 0 4 3 3 6 21
2022/2023265 10 31 23 43 23 70 0 25 23 1 9 7
2023/2024192 7 6 10 18 26 29 12 17 11 17 28 11
2024/2025636 21 30 48 93 29 23 39 63 74 38 64 114
2025/20267.247 83 137 129 779 2.707 590 604 495 512 325 446 440
Totale 8.518